English name | Pazopanib盐酸培唑帕尼 |
Synonyms | Pazopanibforresearch;5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)(methyl)amino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonamide;Pazopanib;CS-1857;Pazopanib(freebase)(GW786034,Votrient);Pazopanib(GW786034);5-(4-((Chemicalbook2,3-diMethyl-3,3a-dihydro-2H-indazol-6-yl)(Methyl)aMino)pyriMidin-2-ylaMino)-2-MethylbenzenesulfonaMide;5-[(4-{[(2,3-diMethyl-2H-indazol-6-yl)Methyl]aMino}pyriMidin-2-yl)aMino]-2-Methylbenzene-1-sulfonaMide |
CAS | 444731-52-6 |
EINECS | |
Molecular formula | C21H23N7O2S |
Molecular weight | 437.52 |
Chemical formula |
|
Density | 1.40 |
Melting point | 285-289°C (dec.) |
Boiling point | 728.8±70.0 °C(Predicted) |
Flashing point | 359℃ |
Solubility | Aqueous Acid (Slightly), DMSO (Slightly, Heated), Methanol (Slightly, Heated) |
Acidity coefficient | 10.19±0.60(Predicted) |
Storage condition | Refrigerator |
Appearance | Yellow powder. |
Colour | White to Beige |
HS | 29350090 |
Use | 1.FDA approved for use in patients with advanced kidney cancer. 2.FDA approved for use in patients with advanced soft tissue sarcomas (STS) who have previously received chemotherapy. |
Package | （According to user requirements） |
Dangerous mark | 43-62/63 |
Risk phrases | 36/37/39-28B |
